<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097551</url>
  </required_header>
  <id_info>
    <org_study_id>P080608</org_study_id>
    <secondary_id>2009-A0109552</secondary_id>
    <nct_id>NCT01097551</nct_id>
  </id_info>
  <brief_title>Endothelial Dysfunction and Diabetes</brief_title>
  <acronym>DENDI</acronym>
  <official_title>Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to progress in the understanding of the early retinal vascular and
      neural abnormalities in patients with diabetes, using a new device, the Dynamic Vessel
      Analyzer. The Dynamic Vessel Analyzer allows to measure the diameter of the retinal vessels
      and to assess how it varies in presence of various stimuli. Then, we will be able to assess
      if a vascular and/or a neural dysfunction is present early in patient with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty patients with type 1 diabetes without diabetic retinopathy and without arterial
      hypertension will be compared with 20 sex and aged-matched healthy control subjects. To
      assess the presence of retinal endothelial dysfunction, the variations of the diameters of
      the retinal vessels will be assessed using the Dynamic Vessel Analyzer, before and after
      flicker light stimulation, sublingual nitroglycerin, neosynephrine eyedrops, and isometric
      contraction. To assess the presence of peripheral endothelial dysfunction, the
      microcirculation of the forearm skin will be studied using iontophoresis with acetylcholine
      delivery, and heat delivery, both coupled with blood flow measurement using laser Doppler. An
      intravital capillaroscopy of the phalanx skin will be performed. The serum levels of CRP,
      ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit)</measure>
    <time_frame>up to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of a peripheral endothelial dysfunction</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between retinal and peripheral endothelial dysfunction (assessment study visit)</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <description>Diabetes duration &gt;= 5 years, age &gt;= 18 and &lt;= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Sex and age-matched control healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trinitrin</intervention_name>
    <description>Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose</description>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neosynephrine 10% collyrium</intervention_name>
    <description>Neosynephrine 10% collyrium: 2 drops</description>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iontophoresis with acetylcholine delivery</intervention_name>
    <description>Iontophoresis with acetylcholine delivery</description>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Vessel Analyzer</intervention_name>
    <description>Dynamic Vessel Analyzer</description>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 1 diabetes: Diabetes duration &gt;= 5 years, age &gt;= 18 and &lt;= 60 years old,
        patients with no visible diabetic retinopathy, and no arterial hypertension

        Healthy subjects: Sex and age-matched control healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For diabetic patients :

               -  age between 20 and 60

               -  type 1 diabetes mellitus

               -  diabetes duration of more than 5 years

               -  no diabetic retinopathy on fundus examination or fundus photographs

               -  no systemic hypertension (defined as systolic blood pressure &gt; 140 mmHg,
                  diastolic blood pressure &gt; 90 mmHg)

          -  For control subjects :

               -  sex and age matching with the diabetic patients

               -  no diabetes, no familial or personal history of elevated blood sugar

               -  Non-diabetic subjects, criteria defined by a fasting glucose &lt;1.10 g / l and an
                  HbA1c &lt;6.5% (according to Lariboisière biochemistry laboratory HbA1c)

               -  no systemic hypertension (defined as systolic blood pressure &gt; 140 mmHg,
                  diastolic blood pressure &gt; 90 mmHg)

               -  Subject with a normal ophthalmologic examination

          -  For both diabetic patients and control subjects :

               -  Subject that has signed informed consent

               -  Subject affiliated to a social security

               -  Subject available for a period of 4 months

        Exclusion Criteria:

          -  For both diabetic patients and control subjects :

               -  presence of cataract or history of cataract surgery

               -  intraocular pressure of more than 21 mmHg

               -  treatment with vasoactive drugs

               -  tobacco consumption of more than 20 cigarettes a day

               -  Contraindications to trinitrin administration: hypersensitivity to trinitrin,
                  treatment by sildenafil, heart disease, severe arterial hypotension, bradycardia,
                  intracranial hypertension

               -  Clinical Raynaud syndrome

               -  Pregnant or breast-feeding subject

               -  Subject whose age is &lt;18 and&gt; 60 years on the day of inclusion

               -  Subject with cardiac disease, severe hypotension (BP &lt;80/50 mmHg), a resting
                  heart rate below 50 beats / minute

               -  Subject intracranial hypertension

               -  Subject with a current consumption of drugs or drugs that may impact vasomotion
                  (antiglaucoma eye drops, vasodilators, antihypertensive drugs). Vasoactive drug
                  use will be prohibited within 24 hours preceding the study.

               -  Subject has not signed an informed consent

               -  Subject not affiliated to a social security

               -  Subject not available for a period of 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amélie LECLEIRE-COLLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascale MASSIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital LARIBOISIERE Service d'Ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>July 2, 2012</last_update_submitted>
  <last_update_submitted_qc>July 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Pathogenesis</keyword>
  <keyword>Dynamic Vessel Analyser</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

